文献速递冠心病外科

冠状动脉旁路移植术血红蛋白优化:加拿大十年多中心经验

Hemoglobin Optimization for Coronary Bypass: A 10-Year Canadian Multicenter Experience.
PubMed 文献 · Ann Thorac Surg · 2018-12-06

该研究回顾2006至2016年加拿大安大略省10个中心行CABG的6145例患者,评估ONTraC血红蛋白优化项目对红细胞输注的影响。结果显示输血率从2006年40.1%降至2016年26.2%(p<0.01),术前评估≥14天者住院时间更短(效应-0.83,95%CI -1.41至-0.25;p<0.01),且输血风险有降低趋势(OR 0.83,95%CI 0.68至1.00;p=0.06)。输血与死亡、感染及住院时间延长独立相关。

要点

  • ONTraC项目10年间CABG患者输血率由40.1%降至26.2%(p<0.01)。
  • 术前评估≥14天者住院时间更短(效应-0.83,95%CI -1.41至-0.25)。
  • 输血独立增加死亡(OR 1.49,95%CI 1.37至1.60)和感染(OR 1.24,95%CI 1.18至1.30)风险。

核心结论

  • 术前血红蛋白优化可能有效减少CABG术后红细胞输注,尤其对术前评估≥14天的患者。

研究设计与样本

  • 回顾性多中心队列研究,纳入2006至2016年加拿大安大略省10个中心行CABG的6145例患者(每中心每年前60例连续患者)。

主要发现

  • 总体45.7%患者术前<14天评估,16.4%术前≥14天评估,37.9%未术前评估。
  • 输血率从2006年40.1%降至2016年26.2%(p<0.01)。
  • 评估≥14天、<14天及未评估患者的输血率分别为26%、28%、28%。
  • 校正基线协变量后,术前评估≥14天者住院时间更短(效应-0.83,95%CI -1.41至-0.25;p<0.01),输血风险有降低趋势(OR 0.83,95%CI 0.68至1.00;p=0.06)。
  • 输血独立关联死亡风险增加(OR 1.49,95%CI 1.37至1.60;p<0.01)、感染风险增加(OR 1.24,95%CI 1.18至1.30;p<0.01)及住院时间延长(效应1.49,95%CI 1.35至1.62;p<0.01)。

临床怎么用

  • 对拟行CABG患者,可考虑术前≥14天进行血红蛋白评估与优化(如铁剂、促红细胞生成素),以降低输血率及缩短住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report our 10-year experience of a multicenter hemoglobin optimization program with the aim to reduce red blood cell transfusion in patients undergoing coronary artery bypass grafting (CABG). METHODS: From 2006 to 2016, patients undergoing CABG at 10 centers in Ontario were referred to the Ontario Transfusion Coordinators (ONTraC) program. Of these, we present data on the first 60 consecutive patients per center, per year (n = 6,145). RESULTS: Overall, 45.7% patients were assessed <14 days preoperatively, 16.4% were assessed ≥14 days preoperatively, and 37.9% were not assessed by ONTraC preoperatively. Transfusion rates fell from 40.1% in 2006 to 26.2% in 2016 (p < 0.01). Patients undergoing assessment were more likely to be older (p < 0.01), female (p < 0.01), and anemic (p < 0.01) versus nonassessed patients. Those patients assessed were more likely to be treated with iron (p < 0.01) and erythropoietin (p < 0.01) preoperatively versus nonassessed patients. Transfusion rates were 26%, 28%, and 28% for patients undergoing assessment ≥14 days prior to operation, <14 days prior to operation, or not at all. After baseline covariate adjustment, patients assessed ≥14 days preoperatively had shorter length of stay (effect -0.83, 95% confidence interval [CI] -1.41 to -0.25; p < 0.01) and a trend towards lower risk of red blood cell transfusion (odds ratio [OR] 0.83, 95% CI 0.68 to 1.00; p = 0.06). Blood transfusion was independently associated with an increased risk of death (OR 1.49, 95% CI 1.37 to 1.60; p < 0.01), infection (OR 1.24, 95% CI 1.18 to 1.30; p < 0.01), and longer hospital length of stay (effect 1.49, 95% CI 1.35 to 1.62; p < 0.01). CONCLUSIONS: The results of this study suggest that preoperative hemoglobin optimization may be effective in reducing red blood cell transfusion after CABG, particularly for patients assessed ≥14 days preoperatively.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Yanagawa B, Rocha RV, Mazine A, et al. Hemoglobin Optimization for Coronary Bypass: A 10-Year Canadian Multicenter Experience. Ann Thorac Surg. 2018. PMID: 30529670. doi:10.1016/j.athoracsur.2018.10.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。